01—Abstract
Summary
Summary of the 8-K filed July 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck (MRK) reported second-quarter 2025 results on July 29, 2025, with total sales of $15.8 billiona, down 2% both nominally and excluding foreign exchange.
The top-line decline was driven by Gardasil/Gardasil 9, which fell 55% to $1.1 billionb on lower demand in China, and by the absence of SIMPONI, which reverted to Johnson & Johnson in October 2024. KEYTRUDA was the standout performer at $8.0 billion, up 9%, and WINREVAIR reached $336 million as it continued its U.S. launch. Animal Health grew 11% to $1.6 billion.
GAAP EPS was $1.76c and non-GAAP EPS was $2.13, versus $2.14 and $2.28 a year earlier. Both figures include a $0.07 charge for the Hengrui Pharma license closing. The most consequential disclosure is the new multiyear optimization initiative, which targets roughly $3.0 billion in annual cost savings by the end of 2027, to be fully reinvested in growth areas.
Within it, a 2025 Restructuring Program carries cumulative pretax costs of about $3.0 billiond (roughly 60% cash) and is expected to deliver $1.7 billion of annual savings, largely realized by end-2027. Merck recorded $649 million of restructuring charges related to this program in Q2. Management also narrowed full-year 2025 guidance: sales of $64.3 to $65.3 billion and non-GAAP EPS of $8.87 to $8.97, which includes about $0.16 of one-time charges.
The outlook excludes the pending Verona Pharma acquisition, expected to close in Q4 2025 for about $10 billion. Investors should weigh the strong KEYTRUDA and pipeline momentum against the Gardasil erosion and the near-term cost of the restructuring. Pipeline news in the quarter was mixed.
Several Phase 3 readouts were positive, including the CORALreef trials of enlicitide and KEYNOTE-B96, but KEYNOTE-937 and LEAP-014 did not reach statistical significance. Upcoming catalysts include the WINREVAIR label-update PDUFA date of October 25, 2025, and the doravirine/islatravir PDUFA date of April 28, 2026.
02—Key points
Key Highlights
- Q2 2025 sales were $15.8 billion, down 2% year over year. KEYTRUDA grew 9% to $8.0 billion, while Gardasil fell 55% to $1.1 billion on lower China demand.
- GAAP EPS was $1.76 (vs. $2.14 in Q2 2024) and non-GAAP EPS was $2.13 (vs. $2.28). Both include a $0.07 charge for the Hengrui Pharma license closing.
- Merck launched a multiyear optimization initiative targeting about $3.0 billion in annual cost savings by end-2027, fully reinvested into growth areas.
- The 2025 Restructuring Program carries about $3.0 billion in cumulative pretax costs (about 60% cash) and targets $1.7 billion in annual savings. Q2 charges were $649 million.
- Full-year 2025 guidance was narrowed: sales of $64.3–$65.3 billion and non-GAAP EPS of $8.87–$8.97. Guidance excludes Verona Pharma and includes about $0.16 of one-time charges.
- Pending acquisition of Verona Pharma for about $10 billion (Ohtuvayre, COPD), expected to close in Q4 2025.
- Mixed pipeline news: positive CORALreef topline results for enlicitide and KEYNOTE-B96, but no statistically significant benefit in KEYNOTE-937 or LEAP-014. WINREVAIR label-update PDUFA is October 25, 2025.
03—Questions
Frequently Asked Questions
Why did Merck's sales decline in Q2 2025 despite strong KEYTRUDA growth?
Gardasil/Gardasil 9 sales fell 55% to $1.1 billion, mainly because of lower demand in China, where sales were zero in the quarter. Lower Japan demand after a catch-up immunization program and SIMPONI's loss of rights in October 2024 also weighed. KEYTRUDA's 9% growth to $8.0 billion and strength in Animal Health (+11%) partially offset these declines.
What is the financial impact of the new restructuring program?
Cumulative pretax costs are estimated at about $3.0 billion, roughly 60% cash, mainly for employee separation and contract termination, with the rest non-cash accelerated depreciation. The program is expected to deliver about $1.7 billion in annual savings, largely by the end of 2027. Merck recorded $649 million of related charges in Q2 2025, and most actions are expected to finish by end-2027, with certain manufacturing actions extending to 2029.
How does the restructuring affect Merck's full-year 2025 earnings outlook?
The non-GAAP EPS guidance of $8.87–$8.97 includes one-time charges totaling about $0.16 per share: $200 million for the Hengrui upfront payment, recorded in Q2, and $300 million for the LaNova MK-2010 technology-transfer milestone, to be recorded in Q3. The restructuring costs are excluded from non-GAAP results, so they do not appear in the EPS guidance. Investors should still note that GAAP results will absorb these charges.
Does the full-year outlook include the Verona Pharma acquisition?
No. The guidance explicitly excludes the anticipated impact of the Verona Pharma acquisition, which Merck expects to close in Q4 2025 for about $10 billion. Guidance also does not assume any additional significant business development transactions. Investors should expect guidance to be updated once the deal closes.
What regulatory catalysts should investors watch next?
The FDA set a PDUFA date of October 25, 2025, for the WINREVAIR label update based on the Phase 3 ZENITH trial, which was granted priority review. The doravirine/islatravir NDA for HIV-1 has a PDUFA date of April 28, 2026. Merck also reported positive topline results from the first two Phase 3 CORALreef trials of enlicitide, an oral PCSK9 inhibitor that would be the first marketed oral option in its class if approved.
04—Continue